Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

BEDMINSTER, N.J., Nov. 1 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported its financial results for the quarter ended September 30, 2007 and provided an update on its 2007 milestones and financial guidance.

Update on 2007 Milestones

With the confirmation of its partnership with Nycomed to develop GATTEX(TM) (teduglutide) outside North America, NPS has now met or exceeded all of its key corporate milestones for 2007. The company announced that it has:

-- Completed the Phase 3 study of GATTEX in short bowel syndrome and

announced top-line results in October;

-- Secured a development and commercialization partner for one of its

late-stage programs;

-- Monetized non-core assets to raise cash;

-- Retired substantially all of its 2008 convertible debt;

-- Reduced cash burn guidance to $70 to $80 million from previous guidance

of $80 to $90 million;

-- Positioned the company to burn between $35 and $45 million in 2008;

-- Explored the development of PREOS and GATTEX in at least one new

indication for each program.

Dr. Tony Coles, president and CEO of NPS, stated: "Our team's diligent efforts this year have strengthened our balance sheet and increased our operating flexibility to drive our late-stage products forward. By monetizing our non-core assets and addressing our debt, we are in a much stronger position to maximize the value of GATTEX and PREOS for patients and shareholders. As a result of the improvements in our financial profile, we are revising our 2007 guidance to reflect the transformation our business has undergone this year."

Business Highlights and Revised 2007 Financial Guidanc
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MENLO PARK, Calif. , July 23, 2014 /PRNewswire/ ... based investment firm, today announced the closing of Sofinnova ... $500 million and in excess of the initial fund ... on helping entrepreneurs build successful biotechnology companies. Consistent with ... companies with promising later stage clinical programs, along with ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
(Date:7/22/2014)... 2014 The Board of Directors of BD (Becton, ... a quarterly dividend of 54.5 cents per common share payable ... 9, 2014. The indicated annual dividend rate is $2.18 per ... a leading medical technology company that partners with customers and ... evolving health needs. Our innovative solutions are focused on improving ...
(Date:7/22/2014)... Dr. Terry Baughn, a senior lecturer in mechanical engineering ... named Engineer of the Year by the North Texas ... , ASME has more than 130,000 members in 158 ... share technology to assist the engineering community, benefiting the ... the Texas Society of Professional Engineers honors banquet. Baughn ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3UT Dallas professor receives Engineer of the Year award 2
... insurance premiums have increased approximately 113% over the past ... by the Kaiser Family Foundation, the reverse is true ... demonstrably cheaper over the past 25 years, due primarily ... competitive market pressures. In addition, many new enhancements to ...
... March 1, 2012 The second phase of ... Healthy Weight," is being announced today by the ... partnership with the Health Resources and Services Administration ... community leaders, from Pasadena to Philadelphia, have been ...
... 2012  AtheroNova Inc. (OTCBB: AHRO), a biotech company focused ... atherosclerotic plaque, today announced that it has initiated the ... its research and development partner CardioNova, Ltd., a Russia ... human clinical studies of AHRO-001. The clinical-grade material will ...
Cached Biology Technology:WestPark Capital's Michael Wechsler Comments on the Life Insurance Market 2Groundbreaking National Program to Reverse Obesity Expands to 50 Locations 2AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001 2AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001 3
(Date:7/23/2014)... 2014 BioCatch, the global leader ... it has been named in Gartner,s Market Guide for ... Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... of several vendors to deliver passive biometric analysis and ... standard feature of at least 30% of one-stop fraud ...
(Date:7/23/2014)... starfish, and corals have in common? Aside from ... that use calcium from their environment to create ... protection. , The July issue of The ... Laboratory, addresses the challenges faced by these species ... carbon dioxide rises, the world,s oceans are becoming ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3Calcification in changing oceans explored in special issue of The Biological Bulletin 2Ancient genetic material from caries bacterium obtained for the first time 2
... that snakes can optimize their vision by controlling the blood ... Kevin van Doorn, PhD, and Professor Jacob Sivak, from the ... blood flow patterns change depending on what,s in its environment. ... Journal of Experimental Biology . "Each species, perception ...
... If cats really had nine lives, one reason might be ... threaten feline health. Yunjeong Kim, a research assistant professor ... has developed a research approach that tackles two deadly infectious ... supported by a $156,342 award from the Morris Animal Foundation. ...
... Whitehead Institute scientists report that the gene mutated ... syndrome also prevents activation of mTORC1, a critical nutrient-sensing ... is an unexpected finding, as some cancers keep this ... expansion. In the case of Birt-Hogg-Dub syndrome, the mutated ...
Cached Biology News:Snakes control blood flow to aid vision 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 3Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway 2
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: